Identification of FcαRI as an Inhibitory Receptor that Controls Inflammation Dual Role of FcRγ ITAM by Pasquier, Benoit et al.
Immunity, Vol. 22, 31–42, January, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.immuni.2004.11.017
Identification of FcRI as an Inhibitory Receptor
that Controls Inflammation: Dual Role of FcR ITAM
2003). Pathogens with mucosal tropism induce a local
SIgA immune response that is protective. Data with se-
rum IgA have revealed an intriguing paradox: they sup-
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considered as an anti-inflammatory isotype (Kerr, 1990).1INSERM U699
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and does not activate complement. In the absence ofBichat Medical School
antigen, IgA downregulates IgG-mediated phagocyto-16 rue Henri Huchard
sis, chemotaxis, bactericidal activity, oxidative burst ac-75870 Paris Cedex 18
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regulatory role of IgA comes from patients with selective
IgA deficiency, who show increased susceptibility to
autoimmune and allergic disorders (Schaffer et al.,Summary
1991). The molecular basis underlying IgA inhibitory
functions is unknown.Serum IgA is considered a discrete housekeeper of
Other Ig isotypes have been reported to have inhibi-the immune system with multiple anti-inflammatory
tory functions by interacting with Fc receptors con-functions, whereas IgA-immune complexes mediate
taining immunoreceptor tyrosine-based inhibitory mo-inflammatory responses. Here, we identify FcRI as a
tifs (ITIM) (Long, 1999). They act by coaggregation withmolecular device that determines the nature of IgA
activating receptors: the crosstalk between the two re-responses. In the absence of sustained aggregation,
ceptors generates a negative signal. This signal is medi-receptor targeting by serum IgA or anti-FcRI Fab
ated either by SH2 domain-containing phosphataseinhibits activating responses of heterologous FcR or
(SHP-1) that consumes protein tyrosine kinase sub-FcRI. The inhibitory mechanism involves recruitment
strates or SH2 domain-containing inositol phosphataseof tyrosine phosphatase SHP-1 to FcRI and impair-
(SHIP) consuming phosphatidylinositol 3,4,5-trisphos-ment of Syk, LAT, and ERK phosphorylation induced
phate, the product of phosphatidylinositol-3-kinase.by FcRI engagement. SHP-1 recruitment is depen-
Both phosphatases were found to associate throughdent on ERK. Conversely, sustained aggregation of
their SH2 domain with given ITIM-bearing receptorsFcRI by multimeric ligands stimulates cell activation
upon ITIM tyrosine phosphorylation by the coaggre-by recruiting high amounts of Syk and aborting SHP-1
gated activating receptor (Coggeshall et al., 2002).binding. Both types of signals require the FcR-ITAM
These phosphatases are then ideally located to targetmotif. Anti-FcRI Fab treatment suppresses manifes-
their substrates, which aborts the activating signal.tations of allergic asthma in FcRI transgenic mice.
FcRI (CD89) is the only IgA Fc receptor expressed onThese findings redefine FcRI as a bifunctional inhibi-
blood myeloid cells, including monocyte/macrophages,tory/activating receptor of the immune system that
dendritic cells, Kupffer cells, neutrophils, and eosino-mediates both anti- and proinflammatory functions
phils (Monteiro and Van De Winkel, 2003). It can bindof IgA.
IgA1 and IgA2 with low affinity (Ka 106 M1). While
monomeric IgA binding to FcRI is transient, polymeric
Introduction IgA and IgA immune complexes bindwith a greater avid-
ity (Wines et al., 2001). FcRI is considered as a unique
The maintenance of immune system homeostasis by member of the FcR family. Its two Ig-like domains are
immunoglobulins (Ig) is essential for protecting the host oriented at right angles; two FcRI molecules can bind
against inflammation and autoimmunity (Ravetch and one IgA molecule within the EC1 domain, at a site com-
Bolland, 2001). Human IgA is the most heterogeneous pletely different from the other FcRs (Herr et al., 2003).
Ig, as it occurs in multiple molecular forms and two The FcRI gene is not located in the FcR gene cluster
subclasses (IgA1 and IgA2), which are differentially dis- but on chromosome 19, inside the leukocyte receptor
tributed between the systemic and mucosal immune cluster (LRC). FcRI is distantly related to other FcRs,
system. Serum IgA, the second most abundant isotype, beingmore homologous to LRC-encoded activating and
aremainlymonomers derived frombonemarrowplasma inhibitory receptors (Davis et al., 2002). Another pecu-
cells (Kerr, 1990), whereas secretory IgA (SIgA) are syn- liarity of FcRI is that it can be expressedwith or without
thesized as dimers by local plasma cells before being physical association to FcR (Launay et al., 1999). This
transported to mucosal surfaces through epithelial cells subunit contains an immunoreceptor tyrosine-based ac-
by the polymeric Ig receptor (Phalipon and Corthesy, tivation motif (ITAM) in its cytoplasmic tail (Kinet, 1999).
The -less FcRI internalizes and recycles IgA to the
cell surface (Launay et al., 1999), while FcR-associated*Correspondence: monteiro@bichat.inserm.fr
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Launay et al., 1999; Shen et al., 2001). Therefore, FcRI
has been described as a solely activating receptor fol-
lowing aggregation by IgA immune complexes (Monteiro
and Van De Winkel, 2003).
As anti-inflammatory effects of serum IgA require
binding of the Fc portion to the cell (Van Epps and
Williams, 1976; Wilton, 1978), we tested whether FcRI
could mediate IgA-induced inhibition. We found that
targeting FcRI in the absence of sustained aggregation
markedly inhibits IgG-dependent phagocytosis and IgE-
induced exocytosis, whereas sustained FcRI aggre-
gation promotes cell activation. Both activation and in-
hibition require the FcR ITAM. The FcRI inhibitory
pathway of heterologous receptors involves ERK-
dependent recruitment of SHP-1, leading to impairment
of signaling induced by heterologous FcRI. By contrast,
in FcRI-activating signals, SHP-1 recruitment is pre-
vented, while Syk recruitment is enhanced. FcRI inhibi-
tory function was demonstrated in vivo in an asthma
model using human FcRI transgenic mice. This study
redefines FcRI as a bifunctional activating/inhibitory
receptor that controls inflammatory responses.
Results
Identification of FcRI as an Inhibitory Receptor
Serum IgA can dampen IgG-mediated phagocytosis
(Wilton, 1978; Nikolova and Russell, 1995). To determine
the role of FcRI in this process, we examined whether
Fab fragments of an anti-FcRI mAb (clone A77) could
inhibit IgG-mediated phagocytosis of E. coli by blood
monocytes. Fab usage permitted FcRI targeting inde-
pendently of IgG receptors. Preincubation ofmonocytes
with A77 Fab inhibited IgG-mediated phagocytosis
(80%) compared to irrelevant Fab fragments (Figure
1). These results identify FcRI as a molecular device
involved in the previously described IgA-induced de-
crease in IgG-mediated phagocytosis.
Figure 1. FcRI Inhibits IgG-Mediated Phagocytosis
Humanmonocytes were preincubated with 10 g/ml anti-FcRI FabType of Interaction with the Ligand Determines
(A77) (C), irrelevant Fab (320) (D), or buffer (A and B). Phagocytosisthe Balance between Inhibitory and Activating
was measured with Texas-red-conjugated E. coli opsonized (B–D)Functions of FcRI
or not (A) with rabbit anti-E. coli IgG, using confocal microscopy.To characterize the requirements for inhibitory or acti-
Overlaid transmission and fluorescence images (mid sections) are
vating function, stable FcRI transfectants were estab- shown (n  6). Mean number (SD) of ingested bacteria per cell
lished in the rat mast cell line RBL-2H3 expressing from different healthy donors was determined by counting at least
three fields (E). Mean percentage inhibition by Fab (*p 	 0.02, Stu-high-affinity IgE receptor (FcRI). Antigen stimulation of
dent’s unpaired t test) is indicated above the bar.IgE-sensitized transfectants induced a strong degranu-
lation response (Figure 2A). Preincubation with anti-
FcRI Fab markedly inhibited this reponse (74%) as
compared to an irrelevant Fab and to nontransfected tory response was also examined. Monovalent anti-
FcRI Fab had a stronger inhibitory effect than divalentcells (Figure 2A). This was observed in two other
transfectants (not shown). The effect was dose depen- F(ab
)2 fragments (Supplemental Figure S1F), whereas
multivalent FcRI crosslinking induced cell activationdent (see Supplemental Figure S1A at http://www.
immunity.com/cgi/content/full/22/1/31/DC1/) and ob- (Figure 2B). No degranulation was observed with anti-
FcRI Fab or F(ab
)2 alone (not shown).served with several anti-FcRI mAbs (A77, A59, A62)
recognizing epitopes within the EC2 domain (Morton et The anti-inflammatory effect of IgA, the physiological
ligand of FcRI, was next investigated. Incubation ofal., 1999) but not with the anti-FcRI mAb A3 (Supple-
mental Figure S1B). Of note, anti-FcRI Fab did neither transfectants with serum IgA but not with IgG signifi-
cantly inhibited IgE-dependent degranulation (43%)modify IgE binding nor FcRI expression in the presence
or absence of IgE or of IgE plus antigen (Supplemental (Figure 2C). As IgA may exert its biological activity at
inflammatory sites where numerous mediators (includ-Figures S1C–S1E). Anti-FcRI Fab purified by gel filtra-
tion had a similar inhibitory action, ruling out a role of ing proteases) accumulate, we examined whether cell
treatment with trypsin modulated IgA-mediated inhibi-aggregates (not shown). The ligand valence in the inhibi-
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inhibition in nontransfected cells (not shown). In con-
trast, sustained aggregation of FcRI by IgA complexes
resulted in degranulation (Figure 2D). These data estab-
lish that IgA interactions with FcRI in the absence of
antigen are profoundly inhibitory, while aggregation by
IgA complexes leads to cell activation.
FcRI Targeting Prevents IgE-Mediated Asthma
We next examined the effect of monomeric targeting of
FcRI on inflammatory responses in vivo using an IgE-
mediated asthma model. As mice do not express FcRI
(Monteiro and Van De Winkel, 2003), the inhibitory func-
tion was tested in transgenic (Tg) mice expressing hu-
man FcRI on myeloid cells (Launay et al., 2000). After
repeated intranasal challenge with IgE immune com-
plexes in the presence of an irrelevant Fab, FcRI Tg
mice developed bronchial hyperreactivity to inhaled
methacholine, as compared toPBS-challengedcounter-
parts (Figures 3A and 3B). This was abrogated in A77
anti-FcRI Fab-treated Tg mice, whereas no effect was
seen in FcRI littermates (Figures 3A and 3B). Pulmo-
nary histology of antigen-challenged Tg mice treated
with the irrelevant Fab showed diffuse alveolar capillary
congestion, with a perivascular and peribronchial in-
flammatory infiltrate consisting mainly of granulocytes
and mononuclear cells (Figures 3F–3H). These features
were absent from lungs of PBS-challenged mice (Fig-
ures 3C–3E). Anti-FcRI Fab administration prevented
antigen-induced airway congestion and infiltration by
inflammatory cells (Figures 3I–3K). No effects were ob-Figure 2. Characterization of FcRI Inhibitory/Activating Functions
served in lungs of FcRI littermates treated with anti-(A) FcRI inhibits IgE-mediated exocytosis. FcRI transfectants
FcRI Fab (not shown).(clone 15.4) and nontransfected (NT) RBL cells were sensitized with
IgE (open bars) or IgE plus 10 g/ml A77 anti-FcRI Fab (black bars)
or irrelevant Fab (320) (gray bars). Degranulation was triggered with FcR ITAM Involvement in FcRI-Inhibitory Signaling
DNP-HSA (0.1g/ml), and net -hexosaminidase release was deter- To determine which type of FcRI, associated or nonas-
mined (*p 	 0.02, n  5). sociated with FcR, accounts for the inhibitory re-
(B) FcRI crosslinking induces degranulation. Cells were sensitized
sponse, we examined transfectants expressing a R209Lwith 10 g/ml of A77 F(ab
)2 fragments (black bars) or 320 (gray
transmembrane FcRI mutant (Figures 4A and 4B) thatbars), stimulated with rabbit anti-mouse F(ab
)2 (RAM at 40 g/ml),
and assayed as in (A) (*p 	 0.02, n  4). cannot associate with the FcR chain (Launay et al.,
(C) Human serum IgA induces inhibition modulated by proteolytic 1999). FcRIR209L elicited neither inhibitory nor activating
treatment. FcRI transfectants were pretreated or not with 1 mg/ml responses (Figures 4C and 4D). Therefore, -less FcRI
trypsin and sensitized overnight with IgE alone (open bars) or with does not directly account for these functions. To assess
IgE plus either serum IgA (black bars) or IgG (gray bars) at 0.2 mg/
the involvement of FcR, a chimeric receptor was con-ml. Degranulation was triggered with DNP-HSA (0.03 g/ml) and
structed by fusing the extracellular and R209L trans-assayed as in (A) (*p 	 0.01, n  6).
(D) IgA complexes mediate cell activation. Cells were sensitized membrane domains of FcRI to the intracytoplasmic tail
with 0.2 mg/ml IgA (black bars), IgG (gray bars), or medium (open of human FcR (Figure 4A). Binding of anti-FcRI Fab
bars) before stimulation with goat anti-human IgA F(ab
)2 (50 g/ml) to FcRIR209L/ chimeric receptor transfectants restored
and assayed as in (A) (*p 	 0.02, Student’s unpaired t test, n  the inhibitory effect to an extent similar to that observed
4). Mean percentage inhibition of degranulation is indicated above
in wild-type transfectants (91% versus 74%) (Figure 4C).the bar.
Aggregation of chimeric receptors induced degranula-
tion, demonstrating that, like wild-type FcRI, they were
able to mediate both activation and inhibition (Figuretory function. This treatment did not affect FcRI expres-
sion (Monteiro et al., 1990) or IgE-mediated degranu- 4D). As FcR does not contain a known inhibitory motif,
the role of FcR ITAM in the inhibitory effect was exam-lation, yet the inhibitory effect of serum IgA was
significantly enhanced (40%) (Figure 2C). A similar en- ined. Single or double Y-to-F ITAM point mutations of
the chimeric receptor were made and transfected intohancement was observed with purified myeloma IgA
(not shown). Two different batches of serum IgA inhib- RBL cells (Figures 4A and 4B). All mutants were no
longer able to mediate inhibitory and activating re-ited degranulation in a dose-dependent manner with a
maximal inhibition at 0.5 mg/ml (Supplemental Figure sponses (Figures 4C and 4D). Of note, all transfectants
expressed significant levels of FcRI at the cell surfaceS1G). Both IgA1 and IgA2 induced significant inhibition
(30%–40%), as compared to human IgG (	5%) (Supple- (Figure 4B) and exhibited over 50% degranulation medi-
ated by FcRI (Figure 4C).mental Figure S1H). The different IgA preparations did
not induce degranulation on their own and showed no We next examined whether FcR could mediate both
Immunity
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Figure 3. FcRI Targeting Prevents Asthma Manifestations
FcRI-transgenic Balb/c mice (Tg) and littermate controls (Lt) were immunized twice with TNP-OVA and repeatedly challenged intranasally
with PBS or with IgE-TNP-OVA immune complexes (IC) in the presence of anti-FcRI (A77) or irrelevant 320 Fab. Bronchial reactivity to inhaled
methacholine was analyzed by whole-body plethysmography.
(A) Changes in airway resistance are expressed as Penh (mean of three mice per group).
(B) Cumulative areas under the curve (AUC) of corresponding Penh values are means  SD of three independent experiments involving at
least eight mice per group (*p 	 0.05, Student’s unpaired t test).
(C–K) Morphological analysis (H&E staining) of lung tissue sections from FcRI Tg mice. Control PBS-challenged mice showing normal
morphology are shown in (C)–(E). Antigen-challenged mice treated with irrelevant Fab, showing peribronchial (F) and epithelial (G) inflammatory
infiltrates and alveolar capillary congestion (H) (see arrows). Antigen-challenged anti-FcRI Fab-treated mice showing substantially less
inflammation and congestion are shown in (I)–(K). Magnification: 10, (C), (F), (I); 100 (D), (E), (G), (H), (J), (K).
activating and inhibitory functions in the context of an- S2A). Similarly, human monomeric IgE, which does not
bind to rat FcRI, was unable to inhibit mouse IgE-medi-other related FcR. As monomeric IgE has been reported
to trigger FcRI signaling (Asai et al., 2001; Kalesnikoff ated degranulation in previously described FcRI hu-
manized RBL cells (Marchand et al., 2003) (Supplemen-et al., 2001), we assessed whether monomeric IgE could
reversely inhibit FcRI-mediated activation in RBL tal Figure S2B). We also established transfectants
expressing a chimeric receptor composed of the extra-transfectants. Two mouse monomeric IgE failed to in-
hibit FcRI-induced exocytosis (Supplemental Figure cellular and transmembrane domains of FcRIIb fused
Inhibitory Function of FcRI
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Figure 4. FcR ITAM Mediates Both Inhibition and Activation in the Context of FcRI
(A) FcRI and FcRIIb constructs are schematically presented.
(B) FcR construct surface expression by transfectants using A77 anti-FcRI, 2.4G2 anti-FcRII/III, or irrelevant 320mAb (gray versus open histo-
grams).
(C) FcR-mediated inhibition of IgE-dependent degranulation. Transfected clones were IgE sensitized alone (open bars) or with 10 g/ml of
anti-FcRI A77 Fab (black bars), anti-FcR 2.4G2 Fab (hatched bars), or irrelevant 320 Fab (gray bars). Degranulation was assayed as in
Figure 2A (*p	 0.02, n 3). Numbers above the bars indicate the percentage inhibition as compared to IgE-induced degranulation (open bars).
(D) FcR-mediated degranulation. Cells were sensitized with 10 g/ml of A77 (black bars), biotinytaled 2.4G2 (hatched black bars), 320 (gray
bars), or biotinytaled 320 (hatched gray bars) F(ab
)2 and stimulated with RAM F(ab
)2 (40 g/ml) or with SA-alkaline phosphatase (50 g/ml).
Net -hexosaminidase release was determined (*p 	 0.02, Student’s unpaired t test, n  4).
to the intracytoplasmic tail of mouse FcR (FcRIIb/), et al., 1998; Launay et al., 1998; Park et al., 1999). To
identify initial events involved in FcRI-inhibitory signal-as described (Bonnerot et al., 1992). Although FcRIIb/
was capable to mediate an activating signal upon ing, we determined the phosphorylation state of the
FcRI-associated FcR after multivalent or monovalentmultimeric engagement with anti-FcR mAb 2.4G2, Fab
fragments of this mAb were unable to inhibit FcRI- ligand interaction. Targeting of the FcRIR209L/ chimeric
receptor by A77 Fab triggered aweaker phosphorylationinduced degranulation (Figures 4C and 4D). These data
underline the importance of the FcRI context for FcR of the FcR than after FcRI-multimeric aggregation
(Figure 5A, left panel). Noninhibitory anti-FcRI A3 Fabto mediate the inhibitory function.
failed to induce phosphorylation (Supplemental Figure
S3). A weak phosphorylation of chimeric receptor wasSHP-1 Recruitment and Cell Desensitization by FcRI
Multivalent crosslinking of FcRI permits recruitment also observed after FcRI activation and treatment with
A77 Fab (Figure 5A, right panel). As phosphatases areand activation of tyrosine kinases and adaptors (Gulle
Immunity
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Figure 5. Monomeric FcRI Targeting Induces Weak Phosphorylation of FcR and SHP-1 Recruitment
(A) Phosphorylation state of FcRI/FcR under multimeric or monomeric targeting conditions. For FcRI stimulatory experiments (left panel),
chimeric FcRIR209L/ RBL transfectants (clone 9.4) were incubated or not () with 10 g/ml of anti-FcRI A77 F(ab
)2 (A77F) for 30 min at 4C,
washed, and stimulated with 40 g/ml rabbit anti-mouse Ig F(ab
)2 (RAM) for 3 min at 37C. Cells were also incubated with 10 g/ml A77 Fab
(A77f) under the same conditions but omitting RAM. For FcRI-inhibitory experiments of FcRI signaling (right panel), cells were sensitized
with IgE anti-DNP plus 10 g/ml A77 Fab (A77f) or 320 Fab (320f) overnight at 37C before stimulation with DNP-HSA (0.1 g/ml) for 3 min at
37C. Cells were lysed in 0.3% Triton X-100 lysis buffer, and equal amounts of A77 Fab were added prior to immunoprecipitation with protein
G, allowing chimera precipitation. Samples were separated by SDS-10% PAGE and transferred onto PVDF membranes before immunoblotting
with 4G10-HRPmAb. To control for equal amounts of chimera, blots were stripped and reprobedwith anti-FcR Ab plus goat anti-rabbit Ig-HRP.
(B) Monomeric targeting of FcRI/FcR elicits SHP-1 recruitment to FcRI. FcRIR209L/ transfectants were incubated with either 10 g/ml
A77 or 320 Fab for indicated times. Cells were lysed in 1% digitonin lysis buffer before immunoprecipitation with protein G and immunoblotting
with anti-SHP-1 Ab plus goat anti-mouse Ig-HRP or anti-SHIP Ab plus anti-rabbit Ig-HRP. To judge effective immunoprecipitation of the
chimeric receptor, blots were stripped and reprobed with anti-FcR Ab plus goat anti-rabbit Ig-HRP. Whole-cell lysates were also analyzed
for the presence of each phosphatase.
(C) SHP-1 recruitment to the FcRI is modulated by FcRI stimulation. Cells were incubated overnight at 37C with or without IgE and in the
presence of either A77 Fab or 320 Fab (10 g/ml). Where indicated, cells were stimulated with DNP-HSA (0.1 g/ml) for 3 min at 37C. Cells
were lysed in 1% digitonin lysis buffer, and 2 g of A77 Fab was added on lysates of cells that had been stimulated with irrelevant 320 Fab
before immunoprecipitation with protein G to enable receptor isolation. The presence of SHP-1 and FcRI/ was examined as in (B).
(D) Prevention of SHP-1 recruitment to FcRI following multimeric engagement. FcRIR209L/ transfectants were incubated with 10 g/ml of
anti-FcRI A77 Fab (A77f) or with preformed complexes of F(ab
)2 (A77F) (10 g/ml) plus RAM F(ab
)2 (40 g/ml) for 1 hr at 37C. The presence
of SHP-1, Syk, and FcRI/ was examined by immunoblotting as in (B). Densitometric analysis of proteins was performed, and the fold
increase in intensity of the recruitment of proteins from crosslinked receptors compared to monovalently targeted receptors (arbitrarily set
as 1) is shown.
known as key mediators in inhibitory pathways, their lent targeting induced recruitment of SHP-1 to the
FcRIR209L/ chimeric receptor, whereas multimeric en-recruitment to the FcRI was then investigated. SHP-1
but not SHIP was recruited in a time-dependent manner gagement prevented this recruitment (Figure 5D). Con-
versely, a stronger recruitement (2- to 3-fold increase)to the FcRI chimera (Figure 5B). No association of
FcRI with SHP-2 was observed (not shown). SHP-1 of Syk kinase was observed after receptor crosslinking
as compared to monovalent Fab interaction based onrecruitment required the FcR ITAM, as inactive ITAM
mutant chimera were unable to recruit SHP-1 to FcRI the total amount of receptor precipitated (Figure 5D).
As SHP-1 is known to dephosphorylate different pro-(not shown). SHP-1 recruitment was enhanced by IgE
and even more so by IgE plus antigen (Figure 5C). We teins of the activation pathway (Coggeshall et al., 2002),
we examined the phosphorylation state of crucial FcRIalso examinedwhether bifunctional inhibitory/activating
properties of FcRI/ reflect a difference between the signaling effectors. FcRI targeting by A77 Fab pre-
vented in a time-dependent manner FcRI-inducedrecruitment of phosphatases and kinases. Monova-
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37
addressed the function of ERK in the FcRI-mediated
inhibitory cascade. Monovalent targeting of FcRI re-
sulted inweakphosphorylationof Syk andERK,whereas
multimeric targeting enhanced both types of responses
(Figure 7A). As expected, pretreatment of cells with a
MEK kinase inhibitor decreased Syk phosphorylation
induced by crosslinking of FcRI but did not substan-
tially modify anti-FcRI Fab-induced phosphorylation of
FcRIR209L/ chimera (not shown) and Syk (Figure 7B). In
constrast,MEKkinase inhibitor abolishedSHP-1 recruit-
ment to FcRI after monovalent targeting (Figure 7C).
The small amount of SHP-1 recruited after multimeric
crosslinking of FcRIwas also reduced byMEK inhibitor
(Figure 7C). Moreover, inactivation of ERK completely
reversed FcRI-inhibitory capacity on FcRI-mediated
exocytosis (Figure 7D), while FcRI degranulation re-
sponses were only partially affected (30  4%) (Figure
7E). Of note, FcRI-induced degranulation was also par-
tially inhibited (36  7%) in the presence of an excess
ofMEK inhibitor (30M), as reported (Zhang et al., 1997).
Discussion
This study unveils important aspects of the physiologic
role of IgA and FcRI as negative regulators of the im-
mune system. In the past, Ig interaction with the relevant
FcR in the absence of antigen was considered a passive
phenomenon with no biological effects. Here, we dem-
onstrate that, in the absence of sustained aggregation,
ligand binding to FcRI inhibits cellular responses initi-
ated by a heterologous receptor, while sustained clus-
tering of FcRI leads to cell activation. Although mono-
meric IgE was recently shown to mediate a spectrumFigure 6. Monomeric FcRI Targeting Induces Sustained Dephos-
phorylation of Syk, LAT, and ERK Activated by FcRI of response in mast cells (Kitaura et al., 2003), our data
indicate that it did not inhibit exocytosis induced by(A) FcRIR209L/ transfectants (clone 9.4) were sensitized overnight
with IgE, washed, and incubated with either A77 or 320 Fab (10 heterologous receptors. The dual function of FcRI pro-
g/ml) for the time indicated. Cells were incubated with 0.1 g/ml vides a molecular basis for the previously observed par-
DNP-HSA for 3 min at 37C. Cells were lysed in 0.3% Triton X-100 adoxical roles of IgA as both an anti- and proinflamma-
lysis buffer and immunoprecipitated with anti-Syk Ab plus protein
tory isotype (Russell et al., 1997). The low naturalA/G beads or directly used as a lysate. Samples were resolved by
frequency of antigen-specific serum IgA antibodiesSDS-10% PAGE, transferred onto PVDF membranes, and immu-
(Kerr, 1990) would favor the physiologic inhibitory func-noblotted with 4G10-HRP mAb or antibodies to Syk, p-LAT, or
p-ERK plus goat anti-rabbit or anti-mouse Ig-HRP. To judge equal tion of FcRI and suggests that the main role of circulat-
loading, blots were stripped and reprobed with anti-Syk or anti- ing IgA is to keep the immune systemunder tight steady-
chainAb plus goat anti-rabbit Ig-HRPor goat anti-mouse Ig-HRP, re- state control. Our findings also suggest that the site
spectively.
where IgA interacts with its receptor may be influential,(B) Kinetics of inhibition of IgE-mediated exocytosis after mono-
as protease treatment of cells substantially enhancedmeric FcRI targeting. RBL cells (crosses) or transfectants express-
the inhibitory effect of FcRI. As inflammatory sites con-ing chimeric FcRIR209L/ (triangles) or FcRIR209L/with double Y-to-F
point mutations within the ITAM motif (Y268/279F) (diamonds) were tain an array of proteases, their action may enhance the
sensitized overnight with IgE anti-DNP and with 10 g/ml A77 Fab. inhibitory potential of the IgA-FcRI interaction, and this
Degranulation was triggered with DNP-HSA (0.1 g/ml), and net in turn would regulate local inflammatory reactions.
-hexosaminidase release was determined (mean  SD, n  3).
A consensus model of negative signaling in the im-
mune system involves ITAM/ITIMcoclustering. Here, the
FcRI inhibitory function takes place in the absence ofphosphorylation of Syk, LAT, and ERK, whereas no inhi-
receptor coaggregation and of an ITIM motif. Therefore,bition was observed with irrelevant Fab (Figure 6A). The
this function cannot be explained by the paired FcRrelatively long incubation time needed to observe maxi-
model, where an ITIM-bearing FcR inhibits the pathwaymal inhibition of kinase phosphorylation by the monova-
triggered by ITAM-containing FcR after their coaggrega-lent ligand paralleled the kinetic data measuring inhibi-
tion (Long, 1999). Our structure-function studies identifytion of IgE-dependent degranulation (Figure 6B).
the FcR ITAM as the module involved in the FcRI
inhibitory pathway. Both FcR ITAM tyrosines are re-
quired for inhibitory and activating functions. This dem-ERK Controls SHP-1 Recruitment to the FcRI
As ERK has been proposed to positively regulate Syk onstrates that under certain conditions ITAM, instead
of promoting activation as initially described, can beactivity byFcRI (Xuet al., 1999) and to inhibit the recruit-
ment of SHP-1 to the TCR (Stefanova et al., 2003), we inhibitory toward a heterologous receptor and can thus
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Figure 7. Involvement of ERK in SHP-1 Recruitment and FcRI-Inhibitory Function
(A) Monomeric targeting of FcRI induces weak phosphorylation of Syk and ERK. FcRIR209L/ transfectants were incubated with 10 g/ml of
A77 Fab or preformed complexes of A77 F(ab
)2 plus RAM F(ab
)2 as in Figure 5D for indicated times. The phosphorylation of Syk and ERK
was examined by immunoblotting as in Figure 6. To judge equal loading and/or effective immunoprecipitation, blots were stripped and
reprobed with anti-Syk Ab or anti-scramblase (SCR) plus goat anti-rabbit or mouse Ig-HRP, respectively.
(B) MEK inhibitor (PD98059) decreases Syk phosphorylation after multimeric FcRI crosslinking. FcRIR209L/ transfectants were treated ()
or not () with 30 M of PD98059 for 30 min and then incubated with 10 g/ml of A77 Fab or preformed complexes of 10 g/ml A77 F(ab
)2
plus 40 g/ml RAM F(ab
)2 in the presence of MEK inhibitor for 1 hr at 37C, lysed in Triton lysis buffer, and immunopreciptated by anti-Syk
Ab plus protein G. To judge effective immunoprecipitation, blots were stripped and reprobed with anti-Syk Ab plus goat anti-rabbit Ig-HRP.
Whole-cell lysates were also analyzed for effective inhibition of ERK by immunoblotting using anti-pERK.
(C) MEK inhibitor abolishes recruitment of SHP-1 after monomeric FcRI targeting. FcRIR209L/ transfectants pre-treated () or not () with
30 M MEK inhibitor were incubated with A77 Fab or preformed complexes of A77 F(ab
)2 plus RAM F(ab
)2, as in (B), in the presence of MEK
inhibitor for 1 hr. Cells were lysed in 1% digitonin lysis buffer, immunoprecipitated with protein G, and immunoblotted with anti-SHP-1 Ab
plus goat anti-mouse Ig-HRP. To judge effective immunoprecipitation of the chimeric receptor, blots were stripped and reprobed with anti-
FcR Ab plus goat anti-rabbit Ig-HRP. Whole-cell lysates were also analyzed for effective inhibition of ERK by immunoblotting using anti-pERK.
(D) MEK inhibitor reverses FcRI-inhibitory function. FcRIR209L/ transfectants were sensitized with IgE anti-DNP overnight and pretreated for
30 min with indicated concentrations of MEK inhibitor prior to incubation with 10 g/ml of A77 Fab (triangles) or 320 Fab (squares) in the
presence of MEK inhibitor for 1 hr. Degranulation was triggered with DNP-HSA (0.1 g/ml), and net -hexosaminidase release was determined.
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be considered as a dual-function motif. Such duality the absence of coaggregation increases local concen-
tration of SHP-1 at the membrane, eliciting a desensiti-was not observed in the context of FcRI or of FcRIIb,
which failed to be inhibitory when targeted monova- zation mechanism. This may represent physiologic situ-
ations where different FcR can be independently engagedlently, indicating the particular nature of the FcRI-
receptor complex. Interestingly, while multimeric bind- in a given cell.
Recent observations described a mechanism bying induces strong FcR ITAM phosphorylation (and cell
activation), monomeric targeting leads to weak phos- which the TCR, an ITAM-bearing receptor, can alterna-
tively mediate inhibition or activation (Stefanova et al.,phorylation of FcR (and inhibition of cell activation),
suggesting that the inhibitory signal originates from in- 2003). While weakly binding ligands predominantly trig-
ger a negative signal by recruitment of SHP-1, inducingcomplete phosphorylation of FcR. This weak phos-
phorylation is revelant with the FcRI-IgA binding reac- receptor desensitization, strongly binding ligands effi-
ciently induce an ERK-dependent activating feedbacktion, which has moderately fast on and off rates: IgA
binding is transient, whereas IgA complexes stabilize loop that competes with SHP-1 recruitment. In contrast,
our data point to a requirement of ERK for the recruit-FcRI aggregates by decreasing the off rate (Wines et
al., 2001; Herr et al., 2003). As in the absence of antigen ment of SHP-1 to FcRI. Since in our experimentsmono-
valent targeting of FcRI preceeds multimeric engage-IgA binding may involve two FcRI (Herr et al., 2003),
one can propose that transient IgA binding could lead ment of targeted FcRI, we propose that FcRI weak
stimulating conditions initiate a low-intensity signalingto an inhibitory signal, while sustained aggregation by
IgA complexes with greater avidity could trigger cellular pathway (low phosphorylation of FcR, Syk, and ERK),
leading to progressive recruitment of SHP-1. This pro-activation. Although this is reminiscent of the kinetic
proofreading model (Torigoe et al., 1998), our findings cessmay promote accumulation of SHP-1 at the plasma
membrane, reaching a threshold level that would in timeargue against such a mechanism. According to this
model, low-affinity ligands of an activating receptor, allow the dephosphorylation of signaling proteins acti-
vated by the heterologous receptor, as is the case ofsuch as FcRI, lead to strong receptor phosphorylation
and trapping of critical effectors in unstable and thus FcRI. In contrast, under multimeric crosslinking of
FcRI, a high-intensity signaling pathway is triggeredineffective signaling complexes. Here, by contrast, tar-
geting of FcRI with anti-FcRI Fab leads to weaker (high phosphorylation of FcR, Syk, and ERK), where
Syk is strongly recruited to FcRI, favoring an activationphosphorylation of FcR and to weaker recruitment of
Syk than observed after multimeric aggregation of signal in which SHP-1 recruitment is aborted. Thus, ERK
critically participates both in an activating pathway thatFcRI. These observations led us to further explorewhat
appeared as a novel inhibitory mechanism. originates from Syk recruitment and in an inhibitory
pathway that involves SHP-1 recruitment.Although FcRI-mediated inhibition does not require
coaggregation with the targeted receptor, our data pro- The powerful inhibitory signal triggered by FcRI
in vitro led us to investigate its therapeutic potential invide evidence for involvement of the tyrosine phospha-
tase SHP-1. ITAM-dependent recruitment of SHP-1 and amurine IgE-mediatedmodel of asthma. Anti-FcRI Fab
treatment prevented allergic hyperresponsiveness andSHIP has been previously demonstrated following acti-
vation of FcRI or FcRIIa (Kimura et al., 1997; Nakamura the accompanying airway inflammation in FcRI-Tg
mice. One of the hallmarks of asthma, leukocyte infiltra-et al., 2002; Ganesan et al., 2003) and is thought to act
as anegative feedback loop regulating activation signals tion, was markedly inhibited by this treatment. Although
FcRI has not been shown to be expressed on mastinduced by their own FcR. In the case of FcRI, SHP-1
acts toward a heterologous receptor. Monomeric tar- cells in humans, it is expressed on several cell types
involved in the inflammatory allergic network, includinggeting of FcRI promotes strong recruitment of SHP-1
as compared to multimeric crosslinking. This recruit- macrophages, dendritic cells, neutrophils, and eosino-
phils (Monteiro and Van De Winkel, 2003). Allergic pa-ment was delayed (1 hr) but long lasting (12 hr), which
differs from previous results showing rapid recruitment tients have also an upregulation of FcRI expression
on eosinophils (Monteiro et al., 1993), emphasizing itsof SHP-1 by TCR (Dittel et al., 1999) under inhibitory
conditions. It correlates with a decreased pattern of potential role as a negative regulator. Therefore, strate-
gies specifically targeting this receptor, particularly inphosphorylation of Syk, LAT, and ERK, which are crucial
effectors of the FcRI activation pathway, explaining the patients refractory to conventional therapy, might be
useful to prevent allergic disorders.strong inhibition of cell activation. Interestingly, simulta-
neous engagement of FcRI (monovalent targeting) and Collectively, the present findings redefine FcRI as a
novel type of molecular switch of the immune system,of the heterologous FcRI (multivalent targeting) en-
hanced SHP-1 recruitment to FcRI, leading to attenua- directing signals toward either an activating or an inhibi-
tory function. Fine tuning of this mechanism dependstion of FcRI signaling. This suggests that a novel type
of crosstalk between FcRI and activating receptors in on several parameters, including the presence of anti-
Data are presented as percent inhibition of FcRI-induced -hexasaminidase release by A77 or 320 Fab (mean  SD, n  3). No reverse
inhibition was observed with vehicle (DMSO).
(E) MEK inhibitor partially affects FcRI-mediated degranulation. FcRIR209L/ transfectants were pretreated for 30 min with indicated concentra-
tions of MEK inhibitor (black circles) or DMSO (open circles) prior to stimulation with preformed complexes of 10 g/ml of biotinylated A77
F(ab
)2 plus SA-alkaline phosphatase (SA-AP; 50 g/ml) in the presence of MEK inhibitor for 45 min, and net -hexosaminidase release was
determined (mean  SD, n  3).
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IgE-FITC or My43 anti-FcRI mAb plus anti-Igh6a (RS3) biotingen, the proteolytic environment, and the relative pro-
(Schuppel et al., 1987) and SA-PE. Cells were analyzed using aportions of the two types of FcRI (with or without FcR).
FACScalibur (Becton Dickinson).These unique features of FcRI-IgA interaction, together
with the observation that FcRI is closely related to
Phagocytosis Assay
inhibitory/activating receptors in the LRC locus (Davis Adherent PBMC were incubated with 10 g/ml A77 Fab or irrelevant
et al., 2002), lead us to propose that selective pressure Fab for 30min at 37C,washed, and incubated at 37C for 30minwith
Texas-red-conjugated E. coli (50 bacteria/cell) (Molecular Probes,during evolution may have generated a single switch
Eugene, OR) opsonized or not with polyclonal rabbit anti-E. coli IgGmolecule, FcRI, capable of mediating either activation
antibodies according to themanufacturer’s instructions. Slideswereor inhibition.
mounted and examined with a confocal laser microscope (LSM 510
Carl Zeiss, Jena, Germany).Experimental Procedures
-Hexosaminidase AssayAnimals
Exocytosis was determined by measuring release of -hexosamini-Balb/c mice transgenic for the human FcRI (line 83) were used
dase (Roa et al., 1997). Briefly, cells were sensitized with IgE anti-(Launay et al., 2000). Mice were bred and maintained at the facilities
DNP (1:200) and test reagents for 1 hr or overnight at 37C, washed,of Bichat Medical School. All experiments were done in accordance
and stimulated with 0.1 or 0.03 g/ml DNP-HSA (Sigma) or withwith national guidelines.
rabbit anti-mouse IgG F(ab
)2 fragment (40 g/ml) for 45 min at 37C
as indicated. In some experiments, cells were stimulated with 2.4G2Ig, Antibodies, and Reagents
F(ab
)2 biotin or A77 anti-FcRI F(ab
)2 biotin (10 g/ml), and degran-The mouse monoclonal Abs A3, A59, A62, and A77, specific for
ulation was triggered by addition of 0.05 mg/ml SA-alkaline phos-FcRI (Monteiro et al., 1992), were used as either F(ab
)2 or Fab
phatase (Southern Biotech Associates).fragments. Other mAbs used were as follows: My 43 anti-FcRI
(Shen et al., 1989), 2.4G2 anti-mouse FcRII/III (Unkeless, 1979),
IgE Immune-Complex-Mediated Allergic Asthma Model30.9 anti-FcRI  chain (Pastorelli et al., 2001), rabbit anti-mouse
FcRI-Tg mice and littermates were immunized intraperitoneallyIgG, and two irrelevant mAbs (clones TPO 6.12 and 320.1). F(ab
)2
with 10 g TNP-OVA (Sigma) in 2 mg of aluminum hydroxide gelwere obtained by pepsin digestion as described (Silvain et al., 1995).
per 25 g of body weight on days 0 and 7. Starting on day 14, miceFab were prepared by pepsin digestion and reduction with 0.01 M
were challenged intranasally for 7 consecutive days with 2 g TNP-cysteine and alkylationwith 0.15M iodoacetamide at pH 7.5. Purified
OVA complexed with 20 g anti-DNP IgE (Zuberi et al., 2000) in theserum IgA (ICN Biomedicals Inc, Aurora, OH) was used. Human
presence of 5 g A77 or irrelevant Fab (clone 320). On days 14 andserum IgG, IgA, and IgE myeloma proteins as well as mouse anti-
20, mice received 50 g A77 or control Fab intraperitoneally. TwelveDNP-specific IgE (clones DNP48, a gift from R. Siraganian, and H1-
hours after the final intranasal challenge, unrestrained conscious-26.82) were obtained as described (Liu et al., 1980; Monteiro et
mice were placed in a whole-body plethysmograph chamberal., 1990; Roa et al., 1997; Marchand et al., 2003). MEK kinase inhibi-
(BUXCO Electronics, Sharon, CT), and 300 mM methacholine wastor PD 98059 was purchased from Calbiochem, La Jolla, CA.
delivered for 60 s. Airway resistance was calculated every minute
for 20 min after methacholine exposure (Zuany-Amorim et al., 1998).Cells and Cell Lines
Animals were anesthetized, lungs were inflated by tracheal injectionHuman PBMC were isolated from healthy volunteers by Ficoll-
of 1 ml of Optimum Cutter Temperature Compound (BDH, Poole,Hypaque density gradient centrifugation. Enriched (70%–80%)
UK), fixed in 4% paraformaldehyde, dehydrated in graded alcohols,monocyte populations were obtained by adherence to plastic (Mon-
and embedded in paraffin. Comparative histopathologic evaluationteiro et al., 1990). RBL-2H3 cells were maintained as described (Roa
of the degree of inflammation was performed on entire H&E-stainedet al., 1997). In some experiments, cells were treated with 1 mg/ml
lung sections.trypsin-TCPK (Sigma, St Louis, MO) in DMEM for 30 min at 37C.
Tyrosine Phosphorylation Assay, Immunoprecipitation,cDNA Constructs, Expression Vectors, and Transfection
and ImmunoblottingWild-type human FcRI and the R209L mutant were transfected
Cells were solubilized in lysis buffer: 50 mM HEPES (pH 7.4), 0.3%into RBL cells as described (Launay et al., 1999). The FcRIR209L/
Triton X-100 (or 1% digitonin), 50 mM NaF, 50 mM NaCl, 1 mMchimera was generated as follows. The extracellular and transmem-
Na3VO4, 30 mM Na4P2O7, 50 U/ml aprotinin, 10 g/ml leupeptin, andbrane domains of the R209L mutant were amplified by PCR (Fwt:
post-nuclear supernatants were prepared. FcRI were immunopre-GGGCTCGAGATGGACCCCAAACAGACCACC and R-: CTTTC
cipitated for 2 hr at 4C with A77 Fab fragment and proteinGCACTTGGATCTTCAGATTTTCAACCAGTATGGCCAA) as well as
G-Sepharose (Amersham-PharmaciaBiotech). Sykwas immunopre-the intracellular domain of human FcR -chain (F-: TTGGCCATAC
cipitated using anti-Syk Ab (Launay et al., 1998). Proteins were re-TGGTTGAAAATCTGAAGATCCAAGTGCGAAAG, R: GGGGGATCC
solved by SDS-PAGE, transferred onto PVDF membranes, and im-TTACTGTGGTGGTTTCTCATG). PCR products were fused by over-
munoblotted with 4G10 anti-PY mAb, anti-SHP-1 mAb (Upstate,lapping extension PCR. Point mutations (Y268F, Y279F, and double
Charlottesville, VA), polyclonal anti-SHIP rabbit Ab (provided by A.Y268/279F) were introduced in the ITAM motif of the FcRIR209L/
Veillette), rabbit anti-FcR Ab, anti-Syk Ab (Launay et al., 1998),chimera by using the same strategy. All constructs were cloned into
anti- chain, anti-scramblase (Pastorelli et al., 2001), anti-phosphopSRNeo (Launay et al., 1999) between XhoI-BamHI restriction sites
LAT (Cell Signaling, Beverly, MA), or anti-phospho ERK mAbs (Up-(bolded in primers), and products were sequenced. The FcRIIb/
state, NY) for 1 hr at room temperature, followed by goat anti-mousechimera was provided by C. Bonnerot (Bonnerot et al., 1992). RBL
Ig or goat anti-rabbit Ig (Jackson ImmunoResearch Laboratories,cells were transfected with 15 g of DNA by electroporation and
West Grove, PA) both coupled to HRP. Membranes were developedselected for FcRI expression and releasing capacity. For each
by ECL (Amersham-Pharmacia).construct, at least three independent transfectants were tested and
found to give comparable results.
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